Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 7, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose critical information regarding its clinical trials, particularly related to its flagship therapeutic candidate, Navacaprant [3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased Neumora common stock starting from September 15, 2023, and they have until April 7, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims to recover losses [2]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora altered the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [3]. - The company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD, which raises concerns about the validity of the trial results [3]. - There were significant deficiencies in the Phase Two trials, particularly regarding patient population size and the male-to-female ratio, which complicates the prediction of outcomes for the KOASTAL-1 study [3].